Arthritis & Rheumatology最新文献

筛选
英文 中文
Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis 间充质基质细胞促进2型常规树突状细胞免疫代谢重编程以减轻系统性硬化症
IF 13.3 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-06 DOI: 10.1002/art.70359
Zhikang Wang, Sha Liu, Xinping Liu, Yang Ou, Yue Zhang, Huamei Li, Mian Liu, Zhonghui Hu, Dandan Wang, Lingyun Sun
{"title":"Mesenchymal Stromal Cells Fuel Immunometabolic Reprogramming of Type 2 Conventional Dendritic Cells to Alleviate Systemic Sclerosis","authors":"Zhikang Wang, Sha Liu, Xinping Liu, Yang Ou, Yue Zhang, Huamei Li, Mian Liu, Zhonghui Hu, Dandan Wang, Lingyun Sun","doi":"10.1002/art.70359","DOIUrl":"https://doi.org/10.1002/art.70359","url":null,"abstract":"Objective To investigate the clinical efficacy and underlying mechanisms of mesenchymal stromal cell (MSC) therapy in systemic sclerosis (SSc). Methods We prospectively evaluated the efficacy of MSC therapy in SSc patients. To elucidate the therapeutic mechanisms, we integrated paired multi‐omics data: proteomics (n=7), metabolomics (n=7), and both bulk (n=6) and single‐cell (n=2) RNA‐seq. Baseline disease‐associated signatures were mainly defined by publicly available datasets of peripheral blood mononuclear cells (PBMCs, 21 SSc vs. 6 healthy donors). Results MSC therapy significantly ameliorated skin fibrosis (median mRSS decrease 7.0 [IQR, 3.8–9.3], <jats:italic>P</jats:italic> &lt; 0.05) and stabilized lung function after 6 months. In parallel with these clinical improvements, plasma proteomic analysis demonstrated that MSC therapy suppressed Hedgehog‐mediated fibrotic pathways ( <jats:italic>P</jats:italic> <jats:sub>adj</jats:sub> &lt; 0.05). Transcriptomic profiling revealed that pathogenic type 2 conventional dendritic cells (cDC2s) exhibit intrinsic oxidative phosphorylation (OXPHOS) defects ( <jats:italic>P</jats:italic> <jats:sub>adj</jats:sub> &lt; 0.05) in SSc. MSC therapy effectively repaired these defects and concurrently suppressed cDC2‐related inflammatory pathways in PBMCs and plasma ( <jats:italic>P</jats:italic> <jats:sub>adj</jats:sub> &lt; 0.05). Consistent with these findings, single‐cell RNA‐seq revealed OXPHOS recovery in cDC2s alongside an increased proportion of homeostatic subsets. Conclusions Our study underscores the MSC‐mediated immunometabolic reprogramming to restore immune homeostasis by targeting upstream OXPHOS defects of cDC2s in SSc. <jats:boxed-text content-type=\"graphic\" position=\"anchor\"> <jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art70359-toc-0001-m.png\"> <jats:alt-text>image</jats:alt-text> </jats:graphic> </jats:boxed-text>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"8 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149087411","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Oral glucocorticoid dose patterns and organ damage in systemic lupus erythematosus – a nationwide cohort study 口服糖皮质激素剂量模式和系统性红斑狼疮的器官损害-一项全国性队列研究
IF 13.3 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-03 DOI: 10.1002/art.70360
Annica Dominicus, Álvaro Gomez, Ngoc V. Nguyen, Karin Blomkvist Sporre, Francesca Faustini, Elisabet Svenungsson, Elizabeth V. Arkema
{"title":"Oral glucocorticoid dose patterns and organ damage in systemic lupus erythematosus – a nationwide cohort study","authors":"Annica Dominicus, Álvaro Gomez, Ngoc V. Nguyen, Karin Blomkvist Sporre, Francesca Faustini, Elisabet Svenungsson, Elizabeth V. Arkema","doi":"10.1002/art.70360","DOIUrl":"https://doi.org/10.1002/art.70360","url":null,"abstract":"Background Evaluating the relationship between glucocorticoid (GC) exposure and organ damage in systemic lupus erythematosus (SLE) is challenging since GC dose varies over time. It is unclear which exposure time window captures the full impact of GC usage. Methods We studied a nationwide cohort of individuals with newly diagnosed SLE 2006‐2022 with follow‐up until January 2024 through a linkage of Swedish national registers. Long‐term oral GC exposure was assessed from pharmacy dispensations to identify which dosing patterns had the strongest association with organ damage overall, and within the ocular, cardiovascular, peripheral vascular, gastrointestinal, diabetes, and malignancy domains. We used Weighted Cumulative Exposure models to estimate the weights of the average daily dose at different time points and determine the relative importance of exposure on organ damage accrual, adjusted for confounders. Results Among 3749 patients with newly diagnosed SLE (82.1% female, median age 48.0 years), the increased risk of first organ damage overall associated with GC dosing was well‐captured by the past 2 years (adjusted HR=1.42 [95%CI 1.31‐1.53] for 5 mg/day), and fairly well captured by the past 1 year (adjusted HR=1.34 [95%CI 1.23‐1.42] for 5 mg/day). For cardiovascular damage, dose patterns over the past 3 years substantially contributed to the associated increased risk. Conclusions In evaluations of overall organ damage in SLE, GC exposure during at least the previous year should be considered to capture the associated increased risk. For cardiovascular damage, the time window for assessing GC exposure and disease activity should be extended to the last 3 years.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"10 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149086302","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis 类风湿关节炎中钙保护蛋白测量的全身炎症与自身抗体负荷之间的关系
IF 13.3 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-03 DOI: 10.1002/art.70357
Caroline Grönwall,Linda Mathsson Alm,Helga Westerlind,Isabel Gehring,Nasim Ghasemzadeh,Niels Steen Krogh,Siri Lillegraven,Espen Haavardsholm,Martina Johannesson,Tore K. Kvien,Johan Rönnelid,Tue Wenzel Kragstrup,Bente Glintborg,Merete Lund Hetland,Hilde Berner Hammer,The Danish Rheumatologic Biobank Study Group, Swedish Rheumatology Quality Register Biobank Study Group(SRQb),Johan Askling,Oliver Hendricks,Estrid Høgdall,Dorte Vendelbo Jensen,Heidi Lausten Munk,Jens Kristian Pedersen,Torkell Ellingsen,Anne Gitte Loft,Ellen‐Margrethe Hauge,Salome Kristensen,Lene Dreyer,Asta Linauskas,Søren Jacobsen,Carl Turesson,Solbritt Rantapää Dahlqvist,Lena Björkman,Alf Kastbom,Eva Baecklund
{"title":"The association between systemic inflammation as measured by calprotectin and autoantibody load in rheumatoid arthritis","authors":"Caroline Grönwall,Linda Mathsson Alm,Helga Westerlind,Isabel Gehring,Nasim Ghasemzadeh,Niels Steen Krogh,Siri Lillegraven,Espen Haavardsholm,Martina Johannesson,Tore K. Kvien,Johan Rönnelid,Tue Wenzel Kragstrup,Bente Glintborg,Merete Lund Hetland,Hilde Berner Hammer,The Danish Rheumatologic Biobank Study Group, Swedish Rheumatology Quality Register Biobank Study Group(SRQb),Johan Askling,Oliver Hendricks,Estrid Høgdall,Dorte Vendelbo Jensen,Heidi Lausten Munk,Jens Kristian Pedersen,Torkell Ellingsen,Anne Gitte Loft,Ellen‐Margrethe Hauge,Salome Kristensen,Lene Dreyer,Asta Linauskas,Søren Jacobsen,Carl Turesson,Solbritt Rantapää Dahlqvist,Lena Björkman,Alf Kastbom,Eva Baecklund","doi":"10.1002/art.70357","DOIUrl":"https://doi.org/10.1002/art.70357","url":null,"abstract":"Background Plasma calprotectin is a marker of neutrophil activity. Its relation to the clinical phenotype and autoantibodies in rheumatoid arthritis (RA) is only partly understood. We therefore aimed to investigate the association between calprotectin and clinical parameters, CRP, ESR, anti‐CCP2 and other anti‐modified protein autoantibodies (AMPAs) in patients with RA. Methods Rheumatoid factor (RF), anti‐cyclic citrullinated peptide 2 (CCP2) isotypes and plasma calprotectin were centrally measured in a cross‐sectional cohort of 4521 Scandinavian RA patients using fluoroenzyme immunoassays. IgG to 15 citrullinated (Cit) and four carbamylated or acetylated (Carb/Acet) peptides were measured by multiplex solid‐phase array. CRP and ESR values were obtained from clinical measurements at the time of blood sampling. Results Calprotectin levels correlated with ESR (ρ=0.53), CRP (ρ=0.47), VAS pain (ρ=0.24), SJC28 (ρ=0.39), and TJC28 (ρ=0.26; p&lt;0.0001 for all). Patients with both elevated CRP (&gt;10mg/L) and calprotectin (&gt;15 AU/ml) (14%, N=613) had significantly higher VAS pain, SJC28, and TJC28 than patients with only elevated CRP (p&lt;0.0001), in early and established disease. Patients with elevated calprotectin, independent of CRP levels, had significantly higher proportions of AMPA positivity including anti‐CCP2. When patients were divided into six groups based on increasing number of Cit/Carb/Acet‐reactivities and anti‐CCP2 IgG levels, elevated calprotectin was associated with increasing AMPA load, particularly in the presence of RF IgM. The differences between AMPA load groups remained after adjusting for sex, age, RF IgM, and disease duration. Conclusions Plasma calprotectin is positively associated with seropositivity and AMPA load by autoantibody levels and the breadth of the autoantibody response.","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"11 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149089274","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply. 回复。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-01 Epub Date: 2026-05-27 DOI: 10.1002/art.70226
Jinjian Fu, Xiaomin Yu, Jun Wang, Qing Zhou, Qiong Fu
{"title":"Reply.","authors":"Jinjian Fu, Xiaomin Yu, Jun Wang, Qing Zhou, Qiong Fu","doi":"10.1002/art.70226","DOIUrl":"10.1002/art.70226","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":"2181-2182"},"PeriodicalIF":9.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147979683","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Extraintestinal Reprogramming of Colon‐Derived CD4+ Intraepithelial Lymphocytes Reveals a Mechanism Underlying the Gut‐Joint Axis 结肠来源的CD4+上皮内淋巴细胞的肠外重编程揭示了肠关节轴的机制
IF 13.3 1区 医学
Arthritis & Rheumatology Pub Date : 2026-10-01 DOI: 10.1002/art.70358
Sarah M. Danielson, Connor Eck, Sucai Liu, Anna Helena Jonsson, Kristine A. Kuhn
{"title":"Extraintestinal Reprogramming of Colon‐Derived CD4+ Intraepithelial Lymphocytes Reveals a Mechanism Underlying the Gut‐Joint Axis","authors":"Sarah M. Danielson, Connor Eck, Sucai Liu, Anna Helena Jonsson, Kristine A. Kuhn","doi":"10.1002/art.70358","DOIUrl":"https://doi.org/10.1002/art.70358","url":null,"abstract":"Objective The gut‐joint axis is a central paradigm in spondyloarthritis, yet the cellular mechanisms linking intestinal and joint immunity remain poorly understood. One potential link is TCRαβ <jats:sup>+</jats:sup> CD4 <jats:sup>+</jats:sup> intraepithelial lymphocytes in the colon (cIELs) that can traffic to extraintestinal tissues, including the joint. Within an inflamed joint, trafficked cIELs display both regulatory and inflammatory capacity. We sought to determine whether this functional identity is determined by an impaired epithelium or shaped by the joint environment. Methods We combined colonoscopy‐guided photoconversion in KikGR mice with single‐cell multiomic profiling and flow cytometry to trace and characterize CD4 <jats:sup>+</jats:sup> cIELs in the spleen and joint‐draining lymph nodes. Intestinal perturbation was induced by dextran sodium sulfate (DSS) and epithelial‐specific major histocompatibility complex class II (MHCII) gene deletion. Results Epithelial‐derived CD4 <jats:sup>+</jats:sup> T cells were enriched for tolerogenic phenotypes, marked by expression of CD73, FR4, and Foxp3. This phenotype persisted despite DSS‐induced intestinal inflammation and was independent of epithelial MHCII expression. However, single cell transcriptomic, epigenetic, and T cell receptor analyses revealed that shared clones undergo tissue‐specific transcriptional reprogramming to more activated states after exiting the epithelium. Conclusions These findings define CD4 <jats:sup>+</jats:sup> cIELs as mobile T cells that retain tolerogenic phenotypes with functional plasticity to a more activated state determined by extraintestinal microenvironments, indicating that the local environment of the joint‐draining lymph nodes, rather than the gut, is important in determining the function of gut‐trafficked CD4 <jats:sup>+</jats:sup> T cells. <jats:boxed-text content-type=\"graphic\" position=\"anchor\"> <jats:graphic xmlns:xlink=\"http://www.w3.org/1999/xlink\" mimetype=\"image/png\" position=\"anchor\" specific-use=\"enlarged-web-image\" xlink:href=\"graphic/art70358-toc-0001-m.png\"> <jats:alt-text>image</jats:alt-text> </jats:graphic> </jats:boxed-text>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"6 1","pages":""},"PeriodicalIF":13.3,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149086041","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Neutrophil-Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis. 小儿慢性复发性多灶性骨髓炎的中性粒细胞驱动炎症。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-09-29 DOI: 10.1002/art.70356
Nataliia Pavliuchenko, Petr Daněk, Hana Malcová, Rudolf Horváth, Dita Cebecauerová, Tomáš Brdička
{"title":"Neutrophil-Driven Inflammation in Pediatric Chronic Recurrent Multifocal Osteomyelitis.","authors":"Nataliia Pavliuchenko, Petr Daněk, Hana Malcová, Rudolf Horváth, Dita Cebecauerová, Tomáš Brdička","doi":"10.1002/art.70356","DOIUrl":"10.1002/art.70356","url":null,"abstract":"<p><strong>Objective: </strong>Chronic recurrent multifocal osteomyelitis (CRMO) is a pediatric autoinflammatory bone disease with poorly defined pathophysiology and limited biomarkers. Murine models implicate neutrophils, neutrophil-derived interleukin-1β, and the adapter protein PSTPIP2, but direct evidence in human CRMO is lacking. This study aims to translate findings from mouse models to human disease by investigating the role of neutrophils and PSTPIP2 in CRMO.</p><p><strong>Methods: </strong>Blood samples from 34 patients with CRMO and 20 controls were analyzed by flow cytometry, biochemical assays, and transcriptomic profiling of purified neutrophils. Patients were evaluated across treatment groups (untreated or treated with nonsteroidal anti-inflammatory drugs, zoledronate, or anti-tumor necrosis factor [anti-TNF] therapy). Neutrophil activation, PSTPIP2 expression, inflammatory gene responses, and correlations with clinical parameters were assessed.</p><p><strong>Results: </strong>CRMO neutrophils displayed chronic activation marked by reduced CD62L expression (P = 0.0016; Mann-Whitney test), which correlated with magnetic resonance imaging lesion burden. PSTPIP2 protein levels were consistently decreased (P = 0.0006) despite elevated messenger RNA expression (P = 0.0005) and absence of coding mutations, suggesting inflammation-associated posttranscriptional regulation. Both neutrophil activation and PSTPIP2 down-regulation normalized in patients receiving anti-TNF therapy. Unlike murine models, IL1B expression and CXCL8 expression were not increased. Transcriptomic profiling (four patients and three controls) identified enrichment of NF-κB signaling and inflammatory and chemotaxis pathways with up-regulation of CCL4, CCL4L2, ATL1, VNN1, H2BC7, and LINC02207 and down-regulation of ISL2. Several transcripts correlated with clinical measures of disease burden.</p><p><strong>Conclusion: </strong>These findings identify neutrophil activation and inflammation-sensitive PSTPIP2 deficiency as central features of human CRMO, suggest chemokines as potential biomarkers, and mechanistically explain why TNF blockade provides clinical benefit.</p>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":" ","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149072897","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Journal Club 杂志俱乐部
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-09-28 DOI: 10.1002/art.70317
{"title":"Journal Club","authors":"","doi":"10.1002/art.70317","DOIUrl":"https://doi.org/10.1002/art.70317","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 10","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068583","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dual-Targeting BCMA–CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution 双靶向BCMA-CD19 CAR-T细胞治疗系统性红斑狼疮:单细胞和免疫库分析揭示免疫重建机制
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-09-28 Epub Date: 2026-04-02 DOI: 10.1002/art.70117
Zhenghao He PhD, Weijia Wang MD, Qianwen Li PhD, Shihao Ding MD, Mingxia Wang MD, Ming Hong PhD
{"title":"Dual-Targeting BCMA–CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution","authors":"Zhenghao He PhD,&nbsp;Weijia Wang MD,&nbsp;Qianwen Li PhD,&nbsp;Shihao Ding MD,&nbsp;Mingxia Wang MD,&nbsp;Ming Hong PhD","doi":"10.1002/art.70117","DOIUrl":"10.1002/art.70117","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>To investigate peripheral immune reconstitution following BCMA–CD19 dual-targeting CAR-T therapy in patients with systemic lupus erythematosus (SLE).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Single-cell RNA sequencing and parallel B cell receptor (BCR) and T cell receptor sequencing were performed on peripheral blood mononuclear cells from five patients with SLE before infusion and after peripheral B cell reconstitution (median 90 days postinfusion). These data were integrated with public datasets from seven patients with SLE treated with CD19 single-targeting CAR-T and three healthy controls for comparative analysis (total N = 15 subjects; 176,182 single cells analyzed).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Dual-targeting CAR-T induced marked depletion of B-lineage populations, including plasma-lineage clusters that persisted after CD19 therapy. Specifically, cluster 2 decreased from 10.70% to 2.67% and cluster 3 from 9.55% to 3.12% in the dual-targeting cohort, whereas cluster 3 increased (6.78%–12.19%) in the single-targeting comparator. In B cells, dual targeting produced greater suppression of RIG-I/MDA5 and type I interferon transcriptional programs than single-targeting therapy. BCR repertoires shifted toward an IGHM-dominant (49.83%–89.19%, <i>P</i> &lt; 0.05), naïve-biased profile, with contraction of pre-enriched class-switched clones and restoration of diversity toward healthy-like profiles. Clinical improvement was significant (mean SLE Disease Activity Index decreased from 9.6 to 2.4, <i>P</i> &lt; 0.05), paralleling these molecular changes.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BCMA–CD19 dual CAR-T therapy was associated with deeper depletion of plasma-lineage compartments and a tendency toward more pronounced reversal of SLE-associated molecular signatures. This exploratory finding suggests a potential advantage of dual targeting in achieving a more comprehensive humoral reset in SLE, which warrants further direct comparative studies to determine clinical superiority.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 10","pages":"2110-2123"},"PeriodicalIF":9.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147359244","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Journal Club 杂志俱乐部
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-09-28 DOI: 10.1002/art.70317
{"title":"Journal Club","authors":"","doi":"10.1002/art.70317","DOIUrl":"https://doi.org/10.1002/art.70317","url":null,"abstract":"","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 10","pages":""},"PeriodicalIF":9.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/art.70317","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149068203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib 由基因表达谱鉴定的狼疮患者亚群对Baricitinib表现出不同的临床反应性。
IF 9.9 1区 医学
Arthritis & Rheumatology Pub Date : 2026-09-28 Epub Date: 2026-04-07 DOI: 10.1002/art.70130
Prathyusha Bachali MS, Amrie Grammer PhD, Peter E. Lipsky MD
{"title":"Subsets of Patients With Lupus Identified by Gene Expression Profiles Exhibit Differential Clinical Responsiveness to Baricitinib","authors":"Prathyusha Bachali MS,&nbsp;Amrie Grammer PhD,&nbsp;Peter E. Lipsky MD","doi":"10.1002/art.70130","DOIUrl":"10.1002/art.70130","url":null,"abstract":"<div>\u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Baricitinib is a JAK1 inhibitor that showed efficacy in patients with systemic lupus erythematosus (SLE) in a phase 2 study but failed to meet the primary endpoint in phase 3 trials. To understand this discrepancy and identify patients with SLE who are responsive to baricitinib, we conducted baseline and longitudinal transcriptomic analysis in patients enrolled in the phase 2 trial.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Whole-blood samples from 272 patients with SLE were analyzed. Clinical response was assessed using SLE Responder Index-4 after 24 weeks of placebo or baricitinib (2 or 4 mg daily). Gene expression profiling was conducted using Gene Set Variation Analysis (GSVA) of 32 immune-related gene modules.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Eight distinct molecular endotypes (A–H) were identified from baseline GSVA scores, with progressively increasing immune disturbances. Baseline demographics were similar across endotypes, with modest but significant differences in anti–double-stranded DNA and complement levels but no SLE Disease Activity Index differences. Significant clinical responses to baricitinib were confined to endotypes D and G (<i>P</i> = 0.004 and 0.048 vs placebo, with effect sizes of 41.54% and 31.89%, respectively). Importantly, patient clustering based on clinical features failed to identify treatment-responsive subsets. Endotype G demonstrated the most pronounced treatment-related transcriptional modulation, with dose-dependent suppression of interferon, JAK1/JAK2/TYK2 signaling, immunoproteasome, and inflammatory pathways evident as early as week 2 and sustained through week 24. Transcriptional changes in response to baricitinib were largely confined to clinical responders in endotype G. Feature importance analysis identified the interferon and Treg cell signatures as major predictors of response.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Transcriptomic analysis identified subsets of patients with SLE responsive to baricitinib.</p>\u0000 \u0000 <div>\u0000 <figure>\u0000 <div><picture>\u0000 <source></source></picture><p></p>\u0000 </div>\u0000 </figure>\u0000 </div>\u0000 </section>\u0000 </div>","PeriodicalId":129,"journal":{"name":"Arthritis & Rheumatology","volume":"78 10","pages":"2138-2148"},"PeriodicalIF":9.9,"publicationDate":"2026-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147495018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书